Epizyme, Inc. (EPZM)
Stock Price:
$12.54 USD
-0.31 (-2.38%)
Updated Aug 7, 2020 11:00 AM EDT - Market open
Key Info
| Market Cap |
1.27B |
| Revenue (ttm) |
13.83M |
| Net Income (ttm) |
-201.88M |
| Shares Out |
101.48M |
| EPS (ttm) |
-2.00 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$12.54 |
| Previous Close |
$12.84 |
| Change ($) |
-0.31 |
| Change (%) |
-2.38% |
| Day's Open |
12.78 |
| Day's Range |
12.51 - 12.80 |
| Day's Volume |
169,586 |
| 52-Week Range |
9.74 - 27.82 |
More Stats
| Market Cap |
1.27B |
| Enterprise Value |
1.04B |
| Earnings Date (est) |
Oct 28, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
101.48M |
| Float |
83.10M |
| EPS (basic) |
-2.09 |
| EPS (diluted) |
-2.00 |
| FCF / Share |
-2.33 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
11.04M |
| Short Ratio |
6.08 |
| Short % of Float |
14.41% |
| Beta |
2.00 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
91.97 |
| PB Ratio |
4.65 |
| Revenue |
13.83M |
| Operating Income |
-204.36M |
| Net Income |
-201.88M |
| Free Cash Flow |
-235.14M |
| Net Cash |
232.03M |
| Net Cash / Share |
2.29 |
| Gross Margin |
-786.92% |
| Operating Margin |
-1,477.56% |
| Profit Margin |
-1,459.70% |
| FCF Margin |
-1,700.12% |
| ROA |
-31.98% |
| ROE |
-65.22% |
| ROIC |
-71.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
7 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$28.38*
(126.41% upside)
Low
16.0
Current: $12.54
High
36.0
Target: 28.38
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 23.80 | 21.70 | 10.00 | 8.01 | 2.56 | 41.41 | 68.48 | 45.22 | 6.94 |
| Revenue Growth | 9.68% | 117% | 24.89% | 212.77% | -93.82% | -39.53% | 51.44% | 551.24% | - |
| Gross Profit | 23.80 | 21.70 | 10.00 | 8.01 | 2.56 | 41.41 | 68.48 | 45.22 | 6.94 |
| Operating Income | -177 | -128 | -137 | -112 | -133 | -55.05 | -3.13 | -0.77 | -20.97 |
| Net Income | -170 | -124 | -134 | -110 | -132 | -55.01 | -3.48 | -0.70 | -20.96 |
| Shares Outstanding | 89.89 | 71.86 | 61.47 | 57.13 | 39.84 | 33.03 | 17.05 | 1.65 | 1.43 |
| Earnings Per Share | -1.93 | -1.72 | -2.18 | -1.93 | -3.32 | -1.67 | -0.22 | -0.72 | -14.65 |
| Operating Cash Flow | -147 | -122 | -120 | -96.37 | -72.93 | -35.36 | -53.73 | 44.15 | 10.00 |
| Capital Expenditures | -0.59 | -0.30 | -0.98 | -0.62 | -0.18 | -2.22 | -0.63 | -1.48 | -0.92 |
| Free Cash Flow | -148 | -122 | -121 | -97.00 | -73.11 | -37.58 | -54.36 | 42.67 | 9.08 |
| Cash & Equivalents | 381 | 240 | 276 | 242 | 208 | 190 | 124 | 97.98 | 33.34 |
| Total Debt | 45.47 | - | 0.11 | 0.73 | 1.29 | - | - | - | - |
| Net Cash / Debt | 336 | 240 | 276 | 241 | 207 | 190 | 124 | 97.98 | 33.34 |
| Assets | 425 | 276 | 289 | 252 | 218 | 199 | 163 | 104 | 37.36 |
| Liabilities | 93.45 | 42.49 | 53.99 | 50.74 | 48.37 | 38.92 | 58.68 | 155 | 88.00 |
| Book Value | 331 | 233 | 235 | 202 | 170 | 160 | 104 | -51.13 | -50.64 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Epizyme, Inc. |
| Country |
United States |
| Employees |
203 |
| CEO |
Robert B. Bazemore |
Stock Information
| Ticker Symbol |
EPZM |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: EPZM |
| IPO Date |
May 31, 2013 |
Description
Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors. It also develops tazemetostat in combination with R-CHOP that is in the Phase Ib/II clinical trials in elderly patients with DLBCL; and tazemetostat in combination with PD-L1 inhibitor, which is in the Phase Ib/II clinical trials for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer. In addition, the company is developing EZM8266, a G9a inhibitor that is in the Phase 1 study for the treatment of sickle cell disease; pinometostat, which is in the preclinical studies stage for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor that is in Phase II clinical trial for patients with solid tumors and NHL; and PRMT1 inhibitor, which is in the Phase 1 clinical trial. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Study Association; and Eisai Co. Ltd. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.